ClinicalTrials.gg
CompletedNCT06734208Updated Dec 4, 2025

A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function

A Phase 1 interventional study of Divarasib in Hepatic Impairment, sponsored by Genentech, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a phase 1, open-label, single-dose, parallel-cohort study to determine the pharmacokinetics (PK) of divarasib in healthy participants and participants with varying degrees of hepatic impairment, as defined by Child-Pugh classification.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria

  • Males or females of non-
  • Within (BMI) range of 18.0 to 45.0 kg/m2

Participants with Hepatic Impairment

  • Considered to have mild, moderate, or severe hepatic impairment by Score classification and has been clinically stable for at least 1 month prior to Screening
  • Chronic (>6 months), stable hepatic insufficiency with features of cirrhosis due to any etiology. Participants must also remain stable throughout the Screening period

Key Exclusion Criteria

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator

Participants with Hepatic Impairment

  • Have a >480 msec for males and >490 msec for females at Screening or Check-in. If any parameter is out of range, the may be repeated for confirmation
  • Any evidence of progressive liver disease that has worsened or is worsening, as determined by the investigator, within 1 month prior to Screening
  • Demonstrated evidence of hepatorenal syndrome
  • Ascites requiring paracentesis or other intervention up to 3 days prior to the study
  • Hepatic encephalopathy Grade 2 or above
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive a single oral dose of Divarasib on Day 1.

    Drug: Divarasib

  • Experimental
    Cohort 2

    Participants will receive a single oral dose of Divarasib on Day 1.

    Drug: Divarasib

  • Experimental
    Cohort 3

    Participants will receive a single oral dose of Divarasib on Day 1.

    Drug: Divarasib

  • Experimental
    Cohort 4

    Participants will receive a single oral dose of Divarasib on Day 1.

    Drug: Divarasib

Interventions

  • Divarasib will be administered as a single oral dose as specified for the respective cohort.

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of Divarasib

    Time frame: Day 1 to Day 7

  2. Maximum Observed Concentration (Cmax) of Divarasib

    Time frame: Day 1 to Day 7

  3. Area Under the Concentration-time Curve from Hour 0 to the last measurable concentration (AUC0-t) of Divarasib

    Time frame: Day 1 to Day 7

  4. Area Under the Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Divarasib

    Time frame: Day 1 to Day 7

Secondary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to Week 10

07

Study locations

4 sites
  • Clinical Pharmacology of Miami, Inc.
    Miami, Florida 33014, United States
  • Panax Clinical Research, LLC
    Miami Lakes, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • American Research Corporation Inc.
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Nov 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 16, 2024
StartActual
Jan 31, 2025
Primary completionActual
Nov 27, 2025
CompletionActual
Nov 27, 2025
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06734208
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Jan 31, 2025
Primary completion
Nov 27, 2025
Completion
Nov 27, 2025
Last update
Dec 4, 2025

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Divarasib

Start the discussion